Ertugliflozin: a new SGLT2 inhibitor for type 2 diabetes

Ertugliflozin (Steglatro) is a new sodiumglucose co-transporter-2 (SGLT2) inhibitor for the treatment of adults with type 2 diabetes. This article examines its place in therapy, clinical trial efficacy and adverse effects.

Read the full article.

Add yours ↓
Web design and marketing agency Leamington Spa